<DOC>
	<DOCNO>NCT02300935</DOCNO>
	<brief_summary>This study investigate combination two drug , trametinib nab-paclitaxel , patient advance unresectable metastatic melanoma . Each drug show activity trial patient melanoma . However , combination two drug study . In trial investigator determine maximum dose drug combination administer patient advance unresectable metastatic melanoma examine safety profile drug combination .</brief_summary>
	<brief_title>Study Trametinib Nab-paclitaxel Patients With Melanoma</brief_title>
	<detailed_description>While treatment melanoma evolve last year , advanced/metastatic melanoma remain aggressive disease poor prognosis . Trametinib nab-paclitaxel demonstrate single-agent activity Phase III trial patient melanoma . The investigator propose investigate drug combination patient advance unresectable metastatic melanoma . This open-label Phase I study design determine maximum tolerate dose ( MTD ) , recommend Phase II dose ( RP2D ) , safety profile trametinib nab-paclitaxel give combination . Patients melanoma know BRAF mutation status receive escalate dos trametinib nab-paclitaxel determine MTD . Once MTD determine additional 6 patient treat MTD establish dose future study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Adults ( ≥18 year ) histologically cytologicallyconfirmed advanced unresectable metastatic melanoma . BRAF mutationpositive wildtype tumor allow . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic , renal , hepatic function Life expectancy ≥12 week Any preexist neuropathy must &lt; grade 2 per Common Technology Criteria Adverse Events ( CTCAE ) version 4.0 More 1 prior cytotoxic chemotherapy regimen metastatic set Prior MEK inhibitor therapy ( prior BRAF inhibitor allow ) Prior nabpaclitaxel ( prior taxane allow ) Use investigational anticancer drug within 21 day 5 halflives ( whichever short ) prior first dose . A minimum 10 day termination investigational drug require . Any drugrelated toxicity resolve Grade 1 baseline . Symptomatic untreated brain metastasis History retinal vein occlusion ( RVO )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>trametinib</keyword>
	<keyword>nab-paclitaxel</keyword>
	<keyword>Mekinist</keyword>
	<keyword>Abraxane</keyword>
	<keyword>unresectable</keyword>
	<keyword>metastatic</keyword>
</DOC>